POLIVY® + R-CHP:

Superior Progression-Free Survival (PFS) vs R-CHOP1,2

in the ITT population (HR [95% CI]: 0.73 [0.57, 0.95], p=0.0177)

Indication1

Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP)is approved in Israel for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma.

Polivy in combination with bendamustine and rituximab is indicated for the treatment of previously treated adult patients with diffuse large B-cell lymphoma who are not candidates for hematopoietic stem cell transplan

In the POLARIX trial, patients treated with POLIVY + R-CHP achieved clinically meaningful improvements vs R-CHOP

 

A notable benefit of POLIVY + R-CHP was shown in high-risk population subgroups including patients with an IPI score of 3-5 and patients with activated B-cell-like (ABC) subtype of DLBCL (See POLARIX Trial - Efficacy results for more information).

Fewer patients with POLIVY + R-CHP had subsequent lines of anti-lymphoma therapy (22.5% with POLIVY + R-CHP vs 30.3% with R-CHOP)

Among those patients, fewer patients receiving POLIVY + R-CHP needed intensive, high-cost, and high-risk therapies such as CAR-T and SCT

(47 patients in the R-CHOP arm vs 26 patients in the POLIVY + R-CHP arm).

 

International hematology experts sharing experience

 

“If we have an intervention that we can use in the frontline setting that reduces the chance of you relapsing, then I think it is really important that we use this in our treatment algorithm.”

 Prof. Andrew Davies

Watch a short video of our expert interview with international senior hematologists Prof. Davies, Prof. Collins and Dr. Osborne regarding their thoughts on the need for less subsequent treatments with POLIVY + R-CHP compared to R-CHOP:

 

 

 

 

“We want to stop any progression events for our patients with high grade lymphoma because second line and subsequent treatments is tough and often the outcomes are poor.”

Dr. Wendy Osborn

Dr. Osborne shares her thoughts on the PFS & OS results from the POLARIX trial:

 

 

“Cure, it is all about cure. Reducing relapses and leading to long term patient benefit and I think it  is what we see with the results of the POLARIX trial.”

Prof. Graham Collins

Prof. Collins and Dr. Osborne on the benefits they foresee of using POLIVY + R-CHP in the first-line setting:

 

 

M-IL-00002501 - videos

Contact The Hematology Team

Roche Pharmaceuticals (Israel) Ltd.

🏢 6 Hacharash St. Hod Hasharon
📞09-9737777
📧  israel.Hematology@roche.com

References:

  1. POLIVY, Israeli MoH approved prescribing information, Aug 2022
  2. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;386(4):351-363.
  3. Herrera AF, et al. Risk Profiling  of Patients  with Previously Untreated Diffuse  Large B-Cell  Lymphoma (DLBCL) by Measuring  Circulating  Tumor DNA (ctDNA):  Results  from the POLARIX  Study. ASH 2022. Oral presentation 542